Join us at the 5th Annual IVI Methods Summit as we delve into the forefront of patient-centered health technology assessment (HTA) to explore its future direction.

The Summit aims to bridge the gap between theory and practice by exploring actionable steps that stakeholders can take to implement patient-centered HTA effectively. Attendees will have the opportunity to engage in thought-provoking discussions, explore patient-focused methodologies, network with thought leaders, and contribute to shaping the future landscape of HTA.

Don’t miss this unique opportunity to be at the forefront of patient-centered health technology assessment and play a vital role in advancing research, policy, and practice. Join us and be part of the conversation that is transforming the future of healthcare.

Register for the Methods Summit

When:
Thursday, March 14, 2024
9:30 AM – 3:00 PM EST

Where:
Venable, LLP
600 Massachusetts Ave, NW
Washington, DC 20001
(In-Person and Live Stream)

REGISTER

Agenda

Join us early to check-in and share coffee with colleagues before the conversation begins.

  • Jason Spangler, MD, Executive Director, Innovation & Value Initiative
  • Ilisa Halpern Paul, MPP, Senior Policy Advisor, Venable, LLP

Our esteemed experts will discuss the intricate intersection of patient journey mapping and health technology assessment (HTA) methodologies. This engaging session with underscore the significance of patient insights and collaborative approaches in shaping contemporary health research.

  • Moderator: Ilisa Halpern Paul, MPP, Venable
  • Kistein Monkhouse, MPA, Patient Orator
  • Melanie Whittington, PhD, Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center

Building from IVI’s recent health equity reports, this session will highlight practical examples of how patients and researchers can partner to incorporate health equity into HTA and explore the research questions that need to come next.

  • Moderator: Ilisa Halpern Paul, MPP, Venable
  • Sneha Dave, Generation Patient
  • Anton Avanceña, PhD, University of Texas at Austin
  • Bellinda King-Kallimanis, PhD, LUNGevity Foundation

Real option value calculates the benefit patients and caregivers receive from treatments that extend life, giving patients the chance to benefit from future treatment advances. Is this new method ready to be put into practice and what would it mean for people with life threatening conditions?

  • Moderator: Rick Chapman, PhD, Innovation and Value Initiative
  • Zubair Ansari, Cancer Support Community
  • Meng Li, PhD, Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center
  • Jon Campbell, PhD, National Pharmaceutical Council

In 2023, IVI and EveryLife Foundation convened a PCORI-funded project on methods to identify common patient-centered outcomes across rare diseases. In this robust discussion, we will ask what makes patient-centered HTA for rare disease different and how can that inform HTA in general?

  • Moderator: Ilisa Halpern Paul, MPP, Venable
  • Dionne Stalling, Rare and Black
  • Simu Thomas, PhD, Alexion Pharmaceuticals
  • Annie Kennedy, EveryLife Foundation for Rare Diseases

This fireside chat will identify opportunities to make patient-centered HTA a reality.

  • Moderator: Jason Spangler, MD, Innovation and Value Initiative
  • Eberechukwu Onukwugha, PhD, University of Maryland
  • Moderator: Ilisa Halpern Paul, MPP, Venable
  • Rick Chapman, PhD, Innovation and Value Initiative

Speakers

Zubair Ansari

Cancer Support Community

Anton Avanceña, PhD

University of Texas at Austin

Jon Campbell, MS, PhD

National Pharmaceutical Council

Rick Chapman, PhD

Innovation and Value Initiative

Sneha Dave

Generation Patient

Annie Kennedy

EveryLife Foundation for Rare Diseases

Bellinda King-Kallimanis, PhD

LUNGevity Foundation

Meng Li, PhD

Center for the Evaluation of Value and Risk in Health

Kistein Monkhouse, MPA

Patient Orator

Eberechukwu Onukwugha, MS, PhD

University of Maryland

Ilisa Halpern Paul, MPP

Venable, LLP

Jason Spangler, MD, MPH, FACPM

Innovation and Value Initiative

Dionne Stalling

Rare and Black

Simu Thomas, PhD

Alexion, AstraZeneca Rare Diseases

Melanie Whittington, PhD, MS

Center for the Evaluation of Value and Risk in Health